MRK
Merck & Co., Inc.
Healthcare · Drug Manufacturers - General · United States · Stock
Score Breakdown
Scored for Dividend Income profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The profitability factor was a primary driver of the composite score, as Merck's FY2025 net margin of 28.1%, operating margin of 32.4%, and ROA of 13.3% reflect best-in-class efficiency.
- The momentum factor weighed heavily on the composite, as the sharp swing from strong quarterly profits to a net loss of -$4,240,000,000 in 2026Q1 and an operating loss of -$3,534,000,000 in the same quarter drove a low momentum score.
- Solid financial health, consistent dividend growth, and modest but positive annual earnings growth provided meaningful support, while the absence of a macro theme assignment and limited revenue growth tempered the overall result.
Why Not Higher
- The severe deterioration in quarterly earnings, with net income collapsing to -$4,240,000,000 in 2026Q1 from a profit of $5,785,000,000 just two quarters earlier, is the single largest drag on the composite score.
- The combination of only +1.3% revenue growth in FY2025 and no macro theme assignment meant that two scoring dimensions contributed relatively little to the total, limiting upside in the composite.
Data Confidence
10 / 10
Very High — full data coverage
Why This Score
Grounded in figures from this company's SEC EDGAR filings — not a restatement of the score itself.
Revenue grew modestly from FY2024 to FY2025, rising +1.3%, while net income increased +6.6% over the same period and diluted EPS improved +8.0% from FY2024 to FY2025.
The model rewarded the meaningful improvement in profitability-driven metrics (net income and EPS growth) but the relatively modest top-line revenue expansion of +1.3% from FY2024 to FY2025 tempered the overall growth score, resulting in a mid-range result.
In FY2025, Merck posted a net margin of 28.1%, an operating margin of 32.4%, and a return on assets of 13.3%.
These figures reflect a highly efficient and profitable business; the model rewarded the combination of wide margins and strong asset productivity, resulting in the maximum available score.
In FY2025, Merck reported a debt-to-equity ratio of 0.94 and total assets of 136,866,000,000.
A debt-to-equity ratio below 1.0 in FY2025 indicates that the company's debt load is roughly in line with its equity base, which the model treated as a manageable leverage position; the large total asset base further supports a solid financial health score.
Quarterly revenue was relatively stable across the last four reported quarters (2025Q2: 15,806,000,000; 2025Q3: 17,276,000,000; 2025Q4: 16,400,000,000; 2026Q1: 16,286,000,000), but net income and operating income deteriorated sharply, with net income swinging from 5,785,000,000 in 2025Q3 to a loss of -4,240,000,000 in 2026Q1, and operating income moving from 6,745,000,000 in 2025Q3 to -3,534,000,000 in 2026Q1.
The model penalized the severe and accelerating decline in bottom-line results over the most recent quarters; despite relatively stable revenues, the sharp swing to net and operating losses in 2026Q1 drove a low momentum score.
Merck's dividends per share have grown consistently from FY2022 through FY2025 (FY2022: 2.80, FY2023: 2.96, FY2024: 3.12, FY2025: 3.28), and the dividend payout ratio in FY2025 stood at 44.8%.
The model rewarded the unbroken multi-year dividend growth trend, while the 44.8% payout ratio in FY2025 suggests the dividend is well-covered by earnings without being excessively conservative or stretched, supporting a solid but not maximum score.
Merck is not currently assigned to any of the 24 tracked macro themes.
Because no macro theme assignment is in place, the model did not award theme-related score points; this reflects the current classification status and is not an indicator of the company's underlying business quality.
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Merck & Co. earned a composite score of 58.7/100 with a Medium risk rating and a Research Further label, reflecting a company with exceptional profitability and solid financial health offset by weak near-term momentum. In FY2025, Merck posted a net margin of 28.1%, an operating margin of 32.4%, and a return on assets of 13.3%, while revenue grew modestly at +1.3% and EPS improved +8.0% year-over-year. However, the most recent quarter (2026Q1) saw a sharp swing to a net loss of -4,240,000,000 and an operating loss of -3,534,000,000, raising meaningful questions about near-term earnings trajectory. The company also maintains a consistent dividend growth record and a manageable debt-to-equity ratio of 0.94, but the absence of a macro theme assignment weighed on the overall composite.
Plain English
Merck is a highly profitable company with strong margins and a growing dividend, but its most recent quarter showed a sudden and steep swing to losses, which is a red flag that warrants closer investigation before drawing conclusions.
Bull Case vs. Bear Case
Bull Case
- Merck's profitability metrics are exceptional, with a net margin of 28.1%, an operating margin of 32.4%, and a return on assets of 13.3% in FY2025, reflecting a highly efficient business.
- The company has grown its dividend per share every year from FY2022 through FY2025 (from $2.80 to $3.28), and the FY2025 payout ratio of 44.8% suggests the dividend is well-covered by earnings.
- With a debt-to-equity ratio of 0.94 and total assets of $136.9 billion in FY2025, Merck's balance sheet reflects a manageable leverage position and a substantial asset base.
Bear Case
- Net income swung from a profit of $5,785,000,000 in 2025Q3 to a steep loss of -$4,240,000,000 in 2026Q1, and operating income similarly collapsed from $6,745,000,000 to -$3,534,000,000, signaling a severe and accelerating deterioration in bottom-line results.
- Top-line revenue growth was only +1.3% from FY2024 to FY2025, indicating limited top-line expansion momentum even before the recent quarterly earnings deterioration.
- Merck is not currently assigned to any of the 24 tracked macro themes, meaning it does not benefit from any thematic tailwind in the model's scoring framework.
What Could Change the Picture
Bullish Triggers
- A return to profitability in subsequent quarters following the 2026Q1 loss, with operating income recovering toward the levels seen in 2025Q2 and 2025Q3, would significantly improve the momentum picture.
- Acceleration in revenue growth beyond the modest +1.3% FY2024-to-FY2025 rate, combined with sustained wide margins, could reinforce the already-strong profitability story.
Bearish Triggers
- If the 2026Q1 net and operating losses persist or deepen in subsequent quarters, the strong FY2025 annual profitability metrics may no longer be representative of the company's current earnings power.
- A meaningful increase in the debt-to-equity ratio above its current 0.94 level, particularly if driven by deteriorating earnings, could shift the financial health assessment in a less favorable direction.
Risk Profile
Medium RiskMerck's debt-to-equity ratio of 0.94 in FY2025 and total assets of $136.9 billion suggest a manageable balance sheet, but the sharp swing to a net loss of -$4,240,000,000 and an operating loss of -$3,534,000,000 in 2026Q1 introduces meaningful near-term earnings risk that investors should monitor closely.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.